Dataset
Dataset ID:
17
Study Design
| Study Design Background | The study provides evidence that SYRO plus MET has a synergistic effect on tumor growth inhibition in both 4T1 and TS/A experimental models |
|---|---|
| Study Description | SYRO plus MET, this radiotracer could be potentially used as a biomarker for the early detection of therapy response |
| Study Type | preclinical |
| Study Subtype | in vivo, ex vivo |
Publication
| Paper Linked | yes |
|---|---|
| Paper Title | Evaluating [18F]FDG and [18F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer models |
| Paper Authors | Rainone P, Valtorta S, Villa C, Todde S, Cadamuro M, Bertoli G, Conconi D, Lavitrano M, Moresco RM |
| Affiliation | University of Milano - Bicocca |
| Paper Journal | International Journal of Molecular Sciences |
| Paper Year | 2023 |
| Paper Doi | https://doi.org/10.3390/ijms241814124 |
| Open Access | yes |
| Updated Year | 2024 |
Study Component
| Multi Modality Images | yes |
|---|---|
| Imaging Modality | PET/CT |
| Radiation | yes |
| Imaging Coverage | whole body |
| Imaging Target | tumor |
Dataset Information
| Institution | University of Milano - Bicocca |
|---|---|
| Pi | Prof. Moresco Rosa Maria |
| Country Of Institution | Italy |
| Imaging Facility | The Laboratory of Imaging for small animals of IBSBC-CNR |
| Euro Bio Imaging Node | MMMI |
| Country Of Imaging Facility | Italy |
| Funding | yes |
| Funding Agency | MOLIM ONCOBRAIN LAB—Innovative methods of molecular imaging for the study of oncological and neurodegenerative diseases, AIRC |
| Grant Number | 2017-NAZ-0146/A, grant n.21635 |
| Dataset Access | limited |
| Duo Data Use Permission | DUO:0000042 |
| Duo Data Use Modifier | DUO:0000046 |
| Duo Investigation | DUO:0000040 |
| Contact Person | paolo.rainone@unimib.it |
In Vivo Experimental Parameters
| Number Of Groups | 6 |
|---|---|
| Types Of Groups | control, cisplatin, MET, cisplatin plus MET, SYRO, and SYRO plus MET |
| Overall Sample Size | 57 |
| Disease Model | breast cancer |
| Organ Or Tissue | mammary gland |
| Sample Size For Each Group | 5 o 4 |
| Randomization | yes, when tumors were palpable, the animals inoculated with 4T1 or TS/A were randomly assigned |
| Blinding | no |
| Statistical Methods | Student’s t-test |
| Species | Mice |
| Strain | Balb/c |
| Immune Status | immunecompetent |
| Sex | female |
| Age | 7-8 weeks |
| Age At Start Experiment | 8 weeks |
| Age At Scanning Experiment S | 56 and 63 days |
| Weight | 24-26 g |
| Genotype | n/a |
| Genetic Manipulation | n/a |
| Gene | n/a |
| Source Of Animals | Charles River Laboratories, Italy |
Experimental Procedures
| Pharmacological Procedures Intervention And Control | yes |
|---|---|
| Pharmacological Drug | metformin, syrosingopine, cisplatin |
| Company | Sigma Aldrich |
| Drug Dose | MET 250 mg/kg, SYRO 7.5 mg/kg, cisplatin 3 mg/kg |
| Frequency Of Administration | MET daily, SYRO three times for week, cisplatin twice a week |
| Vehicle Or Carrier Solution Formulation | All drugs dissolved in saline, except SYRO that was dissolved in DMSO (10% in sterile water) |
| Blood Sampling | no |
| Surgical Procedures Including Sham Surgery | no |
| Pathogen Infection Intervention And Control | no |
| Analgesic Plan To Relieve Pain Suffering And Distress | no |
| Anesthesia For Imaging | yes |
| Anesthesia Type | gas |
| Duration | 20 |
| Anesthesia Drugs | isoflurane |
| Anesthesia Dose | 2% |
| Euthanasia | yes |
| Method | anesthesia |
| Histology | yes |
| Tissues Collected Post Euthanasia | tumor |
| Timing Of Collection | end of study |
| Imaging | yes |
| Frequency Of Imaging | Single scan |
| Timing Of Imaging | t0 and after 7 days of the treatment |
| Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule | yes |
| Contrast Agent Commercial Drug | [18F]FDG, [18F]FLT |
| Contrast Agent Chemical Drug | 18F-fluorodeoxyglucose (FDG), 18F-fluorothymidine (FLT) |
| Contrast Agent Dose | 4.67 ± 0.3 MBq |
| Injection Volume | 0.05 - 0.1 ml |
| Route Of Administration | intravenous |
| Cell Lines | yes |
| Cell Line | 4T1, TS/A |
| Provenance | TS/A (Sigma-Aldrich Inc., St. Louis, MO, USA), 4T1 (ATCC) |
Image Acquisition
| Instrument Vendor | Molecubes |
|---|---|
| Instrument Type | β-cube, X-cube |
| Instrument Specifics | FOV size for PET 130X72 mm, FOV size for CT 37X65 mm |
| Image Acquisition Parameters | CT scan (exam duration: 4 min, X-Ray beam duration: 90 s, kVp: 40, current:400 A, rotation time: 60 s, and angular views: 960), PET scanner for a 20 min static acquisition |
| Correction | decay correction (PET) |
| Raw Data | yes |
Image Data
| Image Type | Processed images (reconstructed PET and CT data) |
|---|---|
| Image Scale | SUV for PET |
| Format Compression | DICOM |
| Dimensions | 3D |
| Overall Number Of Images | 36 |
| Field Of View | Abdominal |
| Dimension Extents | 192x192x384 |
| Pixel Voxel Size Description | 0.4x0.4x0.4 |
| Image Processing Methods | Image reconstruction |
| Image Reconstruction Algorithm | OSEM |
| Quality Control | n/a |
| Image Smoothing Or Filtering Algorithm | n/a |
| Image Registration Algorithm | n/a |
| Ai Enhanced Algorithm | yes |
Analyzed Data
| Data Used For Analysis | SUV, volume measurements |
|---|---|
| Status | complete |
Ontology Terms
| Ncit Imaging | NCIT:C103512 |
|---|---|
| Doid | DOID:1612 |
| Ncit Anatomy | NCIT:C12367 |
| Ncit Species | NCIT:C14238 |
| Ncit Strain | NCIT:C37357 |
| Chebi Pharmaco | CHEBI:6801,CHEBI:32175,CHEBI:27899 |
| Chebi Anesthesia | CHEBI:6015 |
| Chebi Contrast Agent Commercial Name | CHEBI:49134,NCIT:C49093 |
| Chebi Contrast Agent Chemical Name | CHEBI:49134,NCIT:C49093 |
| Clo | CLO:0001401,CLO:0009405 |